| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C33H36N4O6 |
| Purity | |
| Activity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
SG3199 is a cytotoxic pyrrolobenzodiazepine (PBD) dimer that forms interstrand crosslinks in the DNA minor groove. It is the released warhead component of the ADC payload Tesirine (SG3249)[1][2]. It is supplied as a white to off-white solid (C33H36N4O6, MW 584.66) at 98.33% purity.
Physical & Chemical Properties
| CAS Number | 1595275-71-0 |
|---|---|
| Molecular Formula | C33H36N4O6 |
| Molecular Weight | 584.66 g/mol |
| Purity | 98.33% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | O=C1N2[C@](CC(C)=C2)([H])C=NC3=CC(OCCCCCOC4=C(OC)C=C5C(N6[C@](CC(C)=C6)([H])C=NC5=C4)=O)=C(OC)C=C13 |
| Signaling Pathway | Cell Cycle/DNA Damage; Antibody-Drug Conjugate/ADC Related |
| Bioactivity Class | Pyrrolobenzodiazepines |
| Solubility | In Vitro: DMSO: 130 mg/mL (222.35 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | -20°C, protect from light, stored under nitrogen. In solvent: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 130 mg/mL (222.35 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); protect from light, stored under nitrogen; avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 3.25 mg/mL (5.56 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 3.25 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (32.5 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 3.25 mg/mL (5.56 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 3.25 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (32.5 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
SG3199 is potently cytotoxic across a panel of human solid tumor and hematological cancer cell lines (mean GI50 of 151.5 pM). Cells deficient in the DNA repair protein ERCC1 or in homologous recombination repair are more sensitive to SG3199, and the drug shows only moderate susceptibility to multidrug resistance mechanisms[1]. In naked linear plasmid DNA, SG3199 is highly efficient at producing DNA interstrand cross-links, and dose-dependent cross-linking is observed in cells[1].
In Vivo
The in vitro binding of [3H]-SG3199 to plasma proteins from rat (Sprague Dawley), cynomolgus monkey, and human is determined at 0.8, 5, and 50 ng/mL. Plasma protein binding is high in all species: ～97% in rat, ～90% in cynomolgus monkey, and ～95% in human[1]. SG3199 clears very rapidly in rats following i.v. dosing of 0.1 μg/kg, 0.5 μg/kg, and 1 μg/kg. In the 0.5 μg/kg and 1 μg/kg dose groups, clearance is rapid, at 1000 to 1500 mL/h/kg, with a T1/2 of 8 to 42 minutes[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers. Nature 2024 Apr;628(8007):416-423. PMID: 38538786
Identification of 5-Carboxyfluorescein as a Probe Substrate of SLC46A3 and Its Application in a Fluorescence-Based In Vitro Assay Evaluating the Interaction with SLC46A3. Mol Pharm 2023 Jan 2;20(1):491-499. PMID: 36458938
Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes. Bioorg Med Chem Lett 2019 Feb 15;29(4):549-555.
